

---

**ALN-CC5-004 EudraCT Termination Summary**

---

Title of Trial:	A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome
EudraCT Number:	2017-001082-24
Date of Termination:	12-September-2018
Protocol Number:	ALN-CC5-004
Rationale:	The Sponsor terminated the study due to lack of enrollment. No patients were enrolled or dosed. Study was not terminated on the grounds of safety.